Nestorone®/Estradiol Vaginal Ring

The Population Council is developing a new contraceptive vaginal ring designed to have an improved side effect profile, compared to currently marketed products that contain ethinyl estradiol, that could be used by women with high body mass index.  

The Issue

Worldwide, almost half of all pregnancies are unintended—many of which can be attributed to unmet need for contraception, method dissatisfaction, or inconsistent contraceptive use. Among women with an unmet need for contraception, obese women (body mass index greater than or equal to 30) are more likely to report that they are not using any method of contraception. Reducing unmet need and improving method satisfaction among obese women, who account for 15 percent of all adult women globally, is critical to reducing adverse maternal and child health outcomes as obese women are at significantly higher risk of pregnancy-related complications.  

Many currently available hormonal contraceptive options are made with ethinyl estradiol, a synthetic estrogen that has been associated with an increased risk of a venous thromboembolism (VTE). The risk of VTE for obese women using a method based on ethinyl estradiol is five to eight times that of obese women not using a method made with the synthetic estrogen. However, this risk is still lower than that associated with unintended pregnancy and the postpartum period. It is critical to expand the range of contraceptive options that are safe for all individuals.  

The Progress

Researchers at the Population Council have developed a 3-month contraceptive vaginal ring that delivers a daily dose of Nestorone®, a progesterone derivative, and estradiol. Estradiol is a physiological estrogen and is not associated with increased VTE risk. Given the potentially improved safety profile, the vaginal ring is being evaluated for use by women with a BMI up to 35. A Phase 2b study is currently underway to evaluate safety and efficacy. The study is conducted by the NICHD Contraceptive Clinical Trials network in 11 clinical trial sites in the United States. We expect that the new vaginal ring will be a highly effective, easy to use contraceptive method. 

The Impact

A new user-controlled vaginal ring that is safe for women with a high body mass index expands options and may increase method acceptability. The Nestorone® estradiol vaginal ring is likely to be one of the first non-oral contraceptives on the market to deliver hormones that are structurally similar to natural estradiol and progesterone. In addition, the product addresses concerns related to disposal of ethinyl estradiol and is expected to have a lower environmental impact.

Principal Investigator

Key Staff (2)

  • Bruce Variano Senior Scientist, Head of Pharmaceutical Development, Center for Biomedical Research
  • Narender Kumar Senior Scientist, Center for Biomedical Research

Journal Articles (2)